Terms: = Pancreatic cancer AND NOTCH2, Q04721, 4853, ENSG00000134250, AGS2, hN2 AND Treatment
12 results:
1. Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced notch2 inhibition.
Huang G; Cai G; Hu D; Li J; Xu Q; Chen Z; Xu B
Cell Oncol (Dordr); 2022 Dec; 45(6):1329-1346. PubMed ID: 36214997
[TBL] [Abstract] [Full Text] [Related]
2. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy.
Stoop TF; Ateeb Z; Ghorbani P; Scholten L; Arnelo U; Besselink MG; Del Chiaro M
Ann Surg Oncol; 2020 Feb; 27(2):587-596. PubMed ID: 31562603
[TBL] [Abstract] [Full Text] [Related]
4. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
5. Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells.
Capodanno Y; Buishand FO; Pang LY; Kirpensteijn J; Mol JA; Argyle DJ
Endocr Relat Cancer; 2018 Feb; 25(2):131-144. PubMed ID: 29175872
[TBL] [Abstract] [Full Text] [Related]
6. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer.
Imamura T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Ohashi T; Kiuchi J; Nishibeppu K; Konishi H; Shiozaki A; Morimura R; Ikoma H; Ochiai T; Okamoto K; Taniguchi H; Otsuji E
Sci Rep; 2017 Jul; 7(1):5708. PubMed ID: 28720759
[TBL] [Abstract] [Full Text] [Related]
7. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Notch signaling with a notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Yen WC; Fischer MM; Axelrod F; Bond C; Cain J; Cancilla B; Henner WR; Meisner R; Sato A; Shah J; Tang T; Wallace B; Wang M; Zhang C; Kapoun AM; Lewicki J; Gurney A; Hoey T
Clin Cancer Res; 2015 May; 21(9):2084-95. PubMed ID: 25934888
[TBL] [Abstract] [Full Text] [Related]
9. Anti-tumor effect of the extract from qingyihuaji formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1.
Xu Y; Zhu F; Xu S; Liu L
J Tradit Chin Med; 2015 Feb; 35(1):77-83. PubMed ID: 25842732
[TBL] [Abstract] [Full Text] [Related]
10. Involvement of midkine in neuroblastoma tumourigenesis.
Kishida S; Kadomatsu K
Br J Pharmacol; 2014 Feb; 171(4):896-904. PubMed ID: 24116381
[TBL] [Abstract] [Full Text] [Related]
11. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
Güngör C; Zander H; Effenberger KE; Vashist YK; Kalinina T; Izbicki JR; Yekebas E; Bockhorn M
Cancer Res; 2011 Jul; 71(14):5009-19. PubMed ID: 21632553
[TBL] [Abstract] [Full Text] [Related]
12. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
[TBL] [Abstract] [Full Text] [Related]
